A route to new cancer therapies

the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Christophe Lachaud, John Rouse (Lead / Corresponding author)

Research output: Contribution to journalArticle

1 Citation (Scopus)
113 Downloads (Pure)

Abstract

Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

Original languageEnglish
Pages (from-to)701-703
Number of pages3
JournalNature Structural & Molecular Biology
Volume23
Issue number8
DOIs
Publication statusPublished - 3 Aug 2016

Fingerprint

BRCA2 Gene
BRCA1 Gene
Fanconi Anemia
Mutation
Ovarian Neoplasms
Neoplasms
Cell Survival
Breast Neoplasms
Therapeutics

Keywords

  • Cancer
  • DNA damage and repair
  • Tumour-suppressor proteinis

Cite this

@article{51660d4ce5b545158ff0b6ba83a7f790,
title = "A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells",
abstract = "Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.",
keywords = "Cancer, DNA damage and repair, Tumour-suppressor proteinis",
author = "Christophe Lachaud and John Rouse",
year = "2016",
month = "8",
day = "3",
doi = "10.1038/nsmb.3276",
language = "English",
volume = "23",
pages = "701--703",
journal = "Nature Structural & Molecular Biology",
issn = "1545-9993",
publisher = "Nature Publishing Group",
number = "8",

}

A route to new cancer therapies : the FA pathway is essential in BRCA1- or BRCA2-deficient cells. / Lachaud, Christophe; Rouse, John (Lead / Corresponding author).

In: Nature Structural & Molecular Biology, Vol. 23, No. 8, 03.08.2016, p. 701-703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A route to new cancer therapies

T2 - the FA pathway is essential in BRCA1- or BRCA2-deficient cells

AU - Lachaud, Christophe

AU - Rouse, John

PY - 2016/8/3

Y1 - 2016/8/3

N2 - Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

AB - Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

KW - Cancer

KW - DNA damage and repair

KW - Tumour-suppressor proteinis

U2 - 10.1038/nsmb.3276

DO - 10.1038/nsmb.3276

M3 - Article

VL - 23

SP - 701

EP - 703

JO - Nature Structural & Molecular Biology

JF - Nature Structural & Molecular Biology

SN - 1545-9993

IS - 8

ER -